Fengtao You
Suzhou, 215123, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia.
Journal: Cancers
Published: February 03, 2026
Study on the anti-tumor effect of PDL1-CAR-γδT cells constructed with nanobody sequences on glioblastoma.
Journal: American journal of cancer research
Published: May 21, 2025
CD7-Specific Polymersomal Vincristine Delivery Potentiates Chemotherapy in T‑Cell Acute Lymphoblastic Leukemia.
Journal: Polymer science & technology (Washington, D.C.)
Published: February 25, 2025
Vincristine/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia.
Journal: Acta biomaterialia
Published: December 31, 2024
B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors.
Journal: Cancer research
Published: January 18, 2024
Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies.
Journal: European journal of haematology
Published: May 28, 2023
Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
Journal: Life sciences
Published: April 25, 2023
CD7 protein plays a crucial role in T cell infiltration in tumors.
Journal: Heliyon
Published: July 26, 2022
B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Journal: European journal of medical research
Published: February 25, 2022
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 24, 2021
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.
Journal: Transplant immunology
Published: July 25, 2021
Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
Journal: American journal of cancer research
Published: March 09, 2021
Last Updated: 09/26/2026